Receptor Protein-Tyrosine Kinases
"Receptor Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.
| Descriptor ID |
D020794
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400 D12.776.543.750.630
|
| Concept/Terms |
Receptor Protein-Tyrosine Kinases- Receptor Protein-Tyrosine Kinases
- Kinases, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinases, Receptor
- Receptor Protein Tyrosine Kinases
- Receptors, Protein-Tyrosine Kinase
- Protein-Tyrosine Kinase Receptors
- Receptors, Protein Tyrosine Kinase
- PTK Receptors
- Receptors, PTK
- Tyrosine Kinase Receptors
- Protein-Tyrosine Kinase Receptor
- Receptor, Protein-Tyrosine Kinase
- Receptor Protein-Tyrosine Kinase
- Kinase, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinase, Receptor
- Receptor Protein Tyrosine Kinase
- Tyrosine Kinase Linked Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptor Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Receptor Protein-Tyrosine Kinases".
- Receptor Protein-Tyrosine Kinases
- c-Mer Tyrosine Kinase
- Discoidin Domain Receptors
- ErbB Receptors
- fms-Like Tyrosine Kinase 3
- Proto-Oncogene Proteins c-kit
- Proto-Oncogene Proteins c-met
- Proto-Oncogene Proteins c-ret
- Receptor Tyrosine Kinase-like Orphan Receptors
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptor, Fibroblast Growth Factor, Type 4
- Receptor, IGF Type 1
- Receptor, Insulin
- Receptor, Macrophage Colony-Stimulating Factor
- Receptor, trkA
- Receptor, trkB
- Receptor, trkC
- Receptors, Eph Family
- Receptors, Platelet-Derived Growth Factor
- Receptors, TIE
- Receptors, Vascular Endothelial Growth Factor
This graph shows the total number of publications written about "Receptor Protein-Tyrosine Kinases" by people in this website by year, and whether "Receptor Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 4 | 0 | 4 |
| 2013 | 3 | 1 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 3 | 3 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.
-
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications. Br J Cancer. 2024 Aug; 131(3):589-600.
-
Phylogenetic and transcriptomic characterization of insulin and growth factor receptor tyrosine kinases in crustaceans. Front Endocrinol (Lausanne). 2024; 15:1379231.
-
TrkB-mediated sustained neuroprotection is sex-specific and [Formula: see text]-dependent in adult mice following neonatal hypoxia ischemia. Biol Sex Differ. 2024 Jan 04; 15(1):1.
-
Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis. Pathol Res Pract. 2022 Dec; 240:154180.
-
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022 04 10; 40(11):1231-1258.
-
ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma. World J Pediatr. 2022 04; 18(4):285-293.
-
Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head Neck Pathol. 2022 Sep; 16(3):657-669.
-
Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling. Cells. 2021 05 28; 10(6).
-
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021 05 17; 11(5):93.
-
Upregulation of AXL and ß-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. Blood Cancer J. 2021 02 18; 11(2):37.